TrialAnnals of oncology : official journal of the European Society for Medical Oncology2026

Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial.

C Suarez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.